The use of SGLT2 inhibitors vs sulfonylurea was associated with a reduced risk for incident gout and MACE among patients with type 2 diabetes with/at risk for gout.

Scientists from the University of California San Diego have uncovered a new cause of gout that could lead to more effective ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...